Literature DB >> 33144694

Mutant TP53 interacts with BCAR1 to contribute to cancer cell invasion.

Alvin Kunyao Guo1, Yoko Itahana1, Veerabrahma Pratap Seshachalam2, Hui Ying Chow3, Sujoy Ghosh2, Koji Itahana4.   

Abstract

BACKGROUND: Mutant TP53 interacts with other proteins to produce gain-of-function properties that contribute to cancer metastasis. However, the underlying mechanisms are still not fully understood.
METHODS: Using immunoprecipitation and proximity ligation assays, we evaluated breast cancer anti-estrogen resistance 1 (BCAR1) as a novel binding partner of TP53R273H, a TP53 mutant frequently found in human cancers. The biological functions of their binding were examined by the transwell invasion assay. Clinical outcome of patients was analysed based on TP53 status and BCAR1 expression using public database.
RESULTS: We discovered a novel interaction between TP53R273H and BCAR1. We found that BCAR1 translocates from the cytoplasm into the nucleus and binds to TP53R273H in a manner dependent on SRC family kinases (SFKs), which are known to enhance metastasis. The expression of full-length TP53R273H, but not the BCAR1 binding-deficient mutant TP53R273HΔ102-207, promoted cancer cell invasion. Furthermore, among the patients with mutant TP53, high BCAR1 expression was associated with a poorer prognosis.
CONCLUSIONS: The interaction between TP53R273H and BCAR1 plays an important role in enhancing cancer cell invasion. Thus, our study suggests a disruption of the TP53R273H-BCAR1 binding as a potential therapeutic approach for TP53R273H-harbouring cancer patients.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33144694      PMCID: PMC7782524          DOI: 10.1038/s41416-020-01124-9

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  70 in total

Review 1.  Blinded by the Light: The Growing Complexity of p53.

Authors:  Karen H Vousden; Carol Prives
Journal:  Cell       Date:  2009-05-01       Impact factor: 41.582

2.  p130Cas promotes invasiveness of three-dimensional ErbB2-transformed mammary acinar structures by enhanced activation of mTOR/p70S6K and Rac1.

Authors:  Giusy Tornillo; Brigitte Bisaro; Maria del Pilar Camacho-Leal; Mirco Galiè; Paolo Provero; Paola Di Stefano; Emilia Turco; Paola Defilippi; Sara Cabodi
Journal:  Eur J Cell Biol       Date:  2010-10-18       Impact factor: 4.492

3.  Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function.

Authors:  R L Ludwig; S Bates; K H Vousden
Journal:  Mol Cell Biol       Date:  1996-09       Impact factor: 4.272

Review 4.  Integrin signalling adaptors: not only figurants in the cancer story.

Authors:  Sara Cabodi; Maria del Pilar Camacho-Leal; Paola Di Stefano; Paola Defilippi
Journal:  Nat Rev Cancer       Date:  2010-11-24       Impact factor: 60.716

5.  p130Cas substrate domain signaling promotes migration, invasion, and survival of estrogen receptor-negative breast cancer cells.

Authors:  Anna C Cunningham-Edmondson; Steven K Hanks
Journal:  Breast Cancer (Dove Med Press)       Date:  2009-12-07

Review 6.  Structural biology of the tumor suppressor p53.

Authors:  Andreas C Joerger; Alan R Fersht
Journal:  Annu Rev Biochem       Date:  2008       Impact factor: 23.643

7.  Loss of p53 enhances NF-κB-dependent lamellipodia formation.

Authors:  Alvin Kunyao Guo; Yan Yan Hou; Hiroaki Hirata; Shota Yamauchi; Ai Kia Yip; Keng-Hwee Chiam; Nobuyuki Tanaka; Yasuhiro Sawada; Keiko Kawauchi
Journal:  J Cell Physiol       Date:  2014-06       Impact factor: 6.384

8.  Cysteine-rich protein 2 alters p130Cas localization and inhibits vascular smooth muscle cell migration.

Authors:  Chung-Huang Chen; Yen-Chun Ho; Hua-Hui Ho; Il-Chi Chang; Kathrin H Kirsch; Yung-Jen Chuang; Matthew D Layne; Shaw-Fang Yet
Journal:  Cardiovasc Res       Date:  2013-08-23       Impact factor: 10.787

9.  Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth.

Authors:  Jiajun Zhu; Morgan A Sammons; Greg Donahue; Zhixun Dou; Masoud Vedadi; Matthäus Getlik; Dalia Barsyte-Lovejoy; Rima Al-awar; Bryson W Katona; Ali Shilatifard; Jing Huang; Xianxin Hua; Cheryl H Arrowsmith; Shelley L Berger
Journal:  Nature       Date:  2015-09-02       Impact factor: 49.962

10.  The CRAPome: a contaminant repository for affinity purification-mass spectrometry data.

Authors:  Dattatreya Mellacheruvu; Zachary Wright; Amber L Couzens; Jean-Philippe Lambert; Nicole A St-Denis; Tuo Li; Yana V Miteva; Simon Hauri; Mihaela E Sardiu; Teck Yew Low; Vincentius A Halim; Richard D Bagshaw; Nina C Hubner; Abdallah Al-Hakim; Annie Bouchard; Denis Faubert; Damian Fermin; Wade H Dunham; Marilyn Goudreault; Zhen-Yuan Lin; Beatriz Gonzalez Badillo; Tony Pawson; Daniel Durocher; Benoit Coulombe; Ruedi Aebersold; Giulio Superti-Furga; Jacques Colinge; Albert J R Heck; Hyungwon Choi; Matthias Gstaiger; Shabaz Mohammed; Ileana M Cristea; Keiryn L Bennett; Mike P Washburn; Brian Raught; Rob M Ewing; Anne-Claude Gingras; Alexey I Nesvizhskii
Journal:  Nat Methods       Date:  2013-07-07       Impact factor: 28.547

View more
  1 in total

1.  Triptolide promotes degradation of the unfolded gain-of-function Tp53R175H/Y220C mutant protein by initiating heat shock protein 70 transcription in non-small cell lung cancer.

Authors:  Jie Zhou; Junwen Luo; Peiwei Li; Yongjia Zhou; Peichao Li; Fang Wang; Carlo Augusto Mallio; Giulio Rossi; Ahmed Hasnain Jalal; Nenad Filipovic; Zhongxian Tian; Xiaogang Zhao
Journal:  Transl Lung Cancer Res       Date:  2022-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.